[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.155.6. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
March 1993

Pitfalls in Comparing the Costs of Various β-Adrenoreceptor Antagonists-Reply

Author Affiliations

Mobile, Ala

Arch Ophthalmol. 1993;111(3):299-300. doi:10.1001/archopht.1993.01090030017008

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

In Reply.  —In Dr Robin's thoughtful analysis of our article, he accurately points out that the individual β-blockers have distinctive pharmacologic qualities, and I certainly agree that physicians should use these differences to tailor their drug selection to the appropriate clinical situation. The clinical situation for most patients, however, does not demand such selection, and I believe that most physicians currently begin administering a topical β-blocker in the generic sense only. Therefore, for a majority of patients and in a majority of practices, the β-blockers are thought of as "roughly equivalent" with respect to pharmacologic efficacy, safety, and comfort, and thus a cost comparison such as ours could be of interest to a large number of patients in these practices.Although Dr Robin suggests using average wholesale prices of medications as a better method of comparing prices than our "small" sample of retail pharmacy prices, I feel that differences in

First Page Preview View Large
First page PDF preview
First page PDF preview
×